A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel

Trial Profile

A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Athenex
  • Most Recent Events

    • 20 Nov 2017 According to an Athenex media release, this study is expected to finish in 2018.
    • 20 Nov 2017 According to an Athenex media release, results were presented at ESMO Asia 2017 in Singapore, an Annual Congress organized by the European Society for Medical Oncology.
    • 20 Nov 2017 Results presented in an Athenex media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top